ArticleWorld journal of urology2026
Oral solifenacin suspension in the management valve bladder: a pilot study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis pilot study aims to evaluate the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder.
methodsChildren who developed valve bladder after primary posterior urethral valve (PUV) fulguration were prospectively recruited between 2021 and 2025. Inclusion required features of detrusor overactivity, persistent hydronephrosis, or daytime wetting, with exclusion of residual valves/ infection. Solifenacin suspension was administered at 0.07 mg/kg once daily for 12 months. Subjective parameters included voiding frequency, wetting episodes, and side effects. Objective measures included voided volume as a percentage of age-adjusted expected bladder capacity (VV/EBC), detrusor pressure (Pdet‑max), maximum cystometric capacity (MCC), bladder compliance, Society for Fetal Urology (SFU) hydronephrosis grade, and ureteral diameter.
resultsA total of 47 children with a median age of 3 (0.5-5) years presenting with valve bladder features were administered oral solifenacin suspension. At a median follow-up of 16 months, urinary frequency decreased significantly from 12.8 to 7.4 episodes/day (p = 0.001); wetting episodes declined from 4.7 to 1.8/day (p = 0.01); VV/EBC improved from 34% to 60% (p = 0.001); SFU hydronephrosis grade reduced from 3.5 to 2.8 (p = 0.003), ureteral diameter from 11.6 mm to 10.2 mm (p = 0.039). Urodynamic assessment showed a significant decline in Pdet-max from 39.2 to 29.3 (p = 0.001), alongside significant improvements in mean bladder compliance/ cystometric capacity. Treatment was well tolerated, with no major adverse effects.
conclusionsThis pilot study reports the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Further larger studies are warranted.
Indexed as
Identifiers
42771233What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.